Insmed's Blockbuster Drug Brinsupri Drives Record Revenue, Yet Shares Tumble

Insmed posts $306M Q1 revenue driven by Brinsupri, but shares slide 25% as R&D and SG&A expenses weigh on investor sentiment.

The disconnect between Insmed's soaring sales and its sinking stock price has rarely been starker. The biopharma group posted $306 million in first-quarter 2026 revenue — a roughly 230% surge year-over-year — yet its shares hit a fresh 2026 low, sliding 25% to €89.38 in Thursday's trading. A separate report noted a more modest intraday decline of over 7% to €110.38, underscoring the volatility gripping the stock as investors weigh operational momentum against escalating costs.

The star performer was Brinsupri, the recently launched therapy that generated $207.9 million in its first full quarter on the US market. That represented a 44% sequential jump from the prior quarter, cementing its status as the company's primary growth engine. Meanwhile, the established drug Arikayce contributed $98.1 million, a 6% uptick driven largely by international sales.

Despite the top-line fireworks, the bottom line remains under pressure. Insmed narrowed its net loss to $163.6 million, or $0.76 per share — beating the consensus estimate of a $0.96 per-share deficit. But the improvement came at a cost: research spending hit $210 million, while selling, general and administrative expenses reached $247.3 million. The company's cash and securities position of $1.2 billion provides a comfortable cushion, though the burn rate keeps analysts wary.

The clinical pipeline offers reasons for optimism beyond the balance sheet. Insmed's Phase 3b Encore study for Arikayce in patients with MAC lung disease hit all primary and secondary endpoints. Management plans to file a supplemental approval application with the FDA in the second half of 2026. Additionally, a Phase 3 trial for TPIP, an inhaled powder formulation for pulmonary hypertension, kicked off in April, signaling the company's push to diversify beyond its current product base.

For the full year, Insmed's leadership remains bullish, reaffirming guidance that Brinsupri should generate at least $1 billion in revenue, with Arikayce targeting up to $470 million. The next major catalyst arrives in the autumn with the submission of the Encore data, a milestone the company believes will drive further market penetration. The overarching goal: achieve positive cash flow by 2027.